Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study

ClinicalTrials.gov ID: NCT01194830

Public ClinicalTrials.gov record NCT01194830. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 12:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IIIb, 24-week, Randomised, Placebo-controlled, Double-blinded, Efficacy and Safety Study of Linagliptin (BI 1356) in Black/African American Patients With Type 2 Diabetes With a MTT Sub-study

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Study of linagliptin vs. placebo in Black/African American patients with T2DM with a MTT sub-study

Study identification

NCT ID
NCT01194830
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Boehringer Ingelheim
Industry
Enrollment
234 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 2010 (Type not available)
Primary completion
Oct 2011 (Actual)
Completion
Oct 2011 (Actual)
Last update posted
Jan 29, 2014

2010 – 2011

United States locations

U.S. sites
93
U.S. states
22
U.S. cities
79
Facility City State ZIP Site status
1218.75.059 Boehringer Ingelheim Investigational Site Birmingham Alabama — —
1218.75.054 Boehringer Ingelheim Investigational Site Huntsville Alabama — —
1218.75.035 Boehringer Ingelheim Investigational Site Mobile Alabama — —
1218.75.101 Boehringer Ingelheim Investigational Site Toney Alabama — —
1218.75.066 Boehringer Ingelheim Investigational Site Little Rock Alaska — —
1218.75.008 Boehringer Ingelheim Investigational Site Pell City Alaska — —
1218.75.071 Boehringer Ingelheim Investigational Site Anaheim California — —
1218.75.018 Boehringer Ingelheim Investigational Site Chino California — —
1218.75.081 Boehringer Ingelheim Investigational Site Garden Grove California — —
1218.75.109 Boehringer Ingelheim Investigational Site Los Angeles California — —
1218.75.040 Boehringer Ingelheim Investigational Site Colorado Springs Colorado — —
1218.75.047 Boehringer Ingelheim Investigational Site Denver Colorado — —
1218.75.106 Boehringer Ingelheim Investigational Site Bartow Florida — —
1218.75.098 Boehringer Ingelheim Investigational Site Bradenton Florida — —
1218.75.036 Boehringer Ingelheim Investigational Site Chiefland Florida — —
1218.75.105 Boehringer Ingelheim Investigational Site Fort Lauderdale Florida — —
1218.75.083 Boehringer Ingelheim Investigational Site Fort Myers Florida — —
1218.75.002 Boehringer Ingelheim Investigational Site Hialeah Florida — —
1218.75.080 Boehringer Ingelheim Investigational Site Jacksonville Florida — —
1218.75.065 Boehringer Ingelheim Investigational Site Jupiter Florida — —
1218.75.007 Boehringer Ingelheim Investigational Site Miami Florida — —
1218.75.029 Boehringer Ingelheim Investigational Site Miami Florida — —
1218.75.045 Boehringer Ingelheim Investigational Site Miami Florida — —
1218.75.084 Boehringer Ingelheim Investigational Site Miami Florida — —
1218.75.017 Boehringer Ingelheim Investigational Site Ocala Florida — —
1218.75.012 Boehringer Ingelheim Investigational Site Pinellas Park Florida — —
1218.75.074 Boehringer Ingelheim Investigational Site Port Orange Florida — —
1218.75.076 Boehringer Ingelheim Investigational Site South Miami Florida — —
1218.75.003 Boehringer Ingelheim Investigational Site St. Petersburg Florida — —
1218.75.039 Boehringer Ingelheim Investigational Site St. Petersburg Florida — —
1218.75.075 Boehringer Ingelheim Investigational Site Tallahassee Florida — —
1218.75.100 Boehringer Ingelheim Investigational Site Tamarac Florida — —
1218.75.015 Boehringer Ingelheim Investigational Site Tampa Florida — —
1218.75.103 Boehringer Ingelheim Investigational Site West Palm Beach Florida — —
1218.75.049 Boehringer Ingelheim Investigational Site Atlanta Georgia — —
1218.75.067 Boehringer Ingelheim Investigational Site Calhoun Georgia — —
1218.75.016 Boehringer Ingelheim Investigational Site Dunwoody Georgia — —
1218.75.063 Boehringer Ingelheim Investigational Site Lawrenceville Georgia — —
1218.75.056 Boehringer Ingelheim Investigational Site Marietta Georgia — —
1218.75.026 Boehringer Ingelheim Investigational Site Rosswell Georgia — —
1218.75.079 Boehringer Ingelheim Investigational Site Sandy Springs Georgia — —
1218.75.034 Boehringer Ingelheim Investigational Site Snellville Georgia — —
1218.75.001 Boehringer Ingelheim Investigational Site Chicago Illinois — —
1218.75.055 Boehringer Ingelheim Investigational Site Chicago Illinois — —
1218.75.069 Boehringer Ingelheim Investigational Site Owensboro Kentucky — —
1218.75.044 Boehringer Ingelheim Investigational Site Baton Rouge Louisiana — —
1218.75.108 Boehringer Ingelheim Investigational Site Essex Maryland — —
1218.75.086 Boehringer Ingelheim Investigational Site Brockton Massachusetts — —
1218.75.087 Boehringer Ingelheim Investigational Site Watertown Massachusetts — —
1218.75.051 Boehringer Ingelheim Investigational Site Detroit Michigan — —
1218.75.088 Boehringer Ingelheim Investigational Site Flint Michigan — —
1218.75.099 Boehringer Ingelheim Investigational Site Biloxi Mississippi — —
1218.75.006 Boehringer Ingelheim Investigational Site Atco New Jersey — —
1218.75.004 Boehringer Ingelheim Investigational Site Camden New Jersey — —
1218.75.031 Boehringer Ingelheim Investigational Site Brooklyn New York — —
1218.75.095 Boehringer Ingelheim Investigational Site Brooklyn New York — —
1218.75.038 Boehringer Ingelheim Investigational Site Asheboro North Carolina — —
1218.75.009 Boehringer Ingelheim Investigational Site Charlotte North Carolina — —
1218.75.023 Boehringer Ingelheim Investigational Site Charlotte North Carolina — —
1218.75.060 Boehringer Ingelheim Investigational Site Charlotte North Carolina — —
1218.75.005 Boehringer Ingelheim Investigational Site Greensboro North Carolina — —
1218.75.107 Boehringer Ingelheim Investigational Site High Point North Carolina — —
1218.75.020 Boehringer Ingelheim Investigational Site Jacksonville North Carolina — —
1218.75.027 Boehringer Ingelheim Investigational Site Winston-Salem North Carolina — —
1218.75.096 Boehringer Ingelheim Investigational Site Akron Ohio — —
1218.75.090 Boehringer Ingelheim Investigational Site Columbus Ohio — —
1218.75.078 Boehringer Ingelheim Investigational Site Dayton Ohio — —
1218.75.037 Boehringer Ingelheim Investigational Site Philadelphia Pennsylvania — —
1218.75.082 Boehringer Ingelheim Investigational Site Philadelphia Pennsylvania — —
1218.75.010 Boehringer Ingelheim Investigational Site Uniontown Pennsylvania — —
1218.75.028 Boehringer Ingelheim Investigational Site Uniontown Pennsylvania — —
1218.75.091 Boehringer Ingelheim Investigational Site Anderson South Carolina — —
1218.75.072 Boehringer Ingelheim Investigational Site Columbia South Carolina — —
1218.75.068 Boehringer Ingelheim Investigational Site Greenwood South Carolina — —
1218.75.097 Boehringer Ingelheim Investigational Site Greer South Carolina — —
1218.75.024 Boehringer Ingelheim Investigational Site Brentwood Tennessee — —
1218.75.025 Boehringer Ingelheim Investigational Site Collierville Tennessee — —
1218.75.011 Boehringer Ingelheim Investigational Site Germantown Tennessee — —
1218.75.042 Boehringer Ingelheim Investigational Site Humboldt Tennessee — —
1218.75.030 Boehringer Ingelheim Investigational Site Memphis Tennessee — —
1218.75.050 Boehringer Ingelheim Investigational Site Memphis Tennessee — —
1218.75.053 Boehringer Ingelheim Investigational Site Dallas Texas — —
1218.75.057 Boehringer Ingelheim Investigational Site Houston Texas — —
1218.75.064 Boehringer Ingelheim Investigational Site Houston Texas — —
1218.75.104 Boehringer Ingelheim Investigational Site Houston Texas — —
1218.75.043 Boehringer Ingelheim Investigational Site Houton Texas — —
1218.75.022 Boehringer Ingelheim Investigational Site San Antonio Texas — —
1218.75.058 Boehringer Ingelheim Investigational Site Sugar Land Texas — —
1218.75.033 Boehringer Ingelheim Investigational Site Tomball Texas — —
1218.75.102 Boehringer Ingelheim Investigational Site Tomball Texas — —
1218.75.094 Boehringer Ingelheim Investigational Site Waco Texas — —
1218.75.092 Boehringer Ingelheim Investigational Site Whitney Texas — —
1218.75.019 Boehringer Ingelheim Investigational Site Virgnia Beach Virginia — —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01194830, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 29, 2014 · Synced Oct 28, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01194830 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →